Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Related to this article
The top 5 OncLive TV videos of the week.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
Advertisement
Advertisement
Trending on OncLive
1
Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma
2
VS-7375 Elicits Responses in KRAS G12D–Mutated Pancreatic Cancer
3
Chronicity of Immune-Related AEs Drives QOL Burden With Adjuvant Checkpoint Inhibition in Resected RCC
4
Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers
5